Haloperidol and Haloperidol Decanoate

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.010

7 - Haloperidol and Haloperidol Decanoate

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

Haloperidol is among the most extensively studied of all antipsychotics. By 1996, 18 fixed-dose haloperidol trials were in the literature [7, 8], and a 1998 paper noted that 50 studies had been published on haloperidol plasma levels, though many had significant methodological limitations [9]. This clinical database has been supplemented by numerous single photon (SPECT) and, later, Positron Emission Tomography (PET) imaging studies of dopamine D2 receptor occupancy, starting in 1988 [10–12, 1].

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 157 - 173

DOI: https://doi.org/10.1017/9781009002103.010 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Van Putten, T., Marder, S. R., Wirshing, W. C., et al. (1991). Neuroleptic plasma levels. Schizophr Bull, 17, 197–216.Google Scholar

Wei, F. C., Jann, M. W., Lin, H. N., et al. (1996). A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psychiatry, 57, 298–302.Google Scholar

Kapur, S., Zipursky, R., Roy, P., et al. (1997). The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: A PET study. Psychopharmacology, 131, 148–152.Google Scholar

Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254–264.Google Scholar

Regenthal, R., Kunstler, U., Junhold, U., et al. (1997). Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Int Clin Psychopharmacol, 12, 255–261.Google Scholar

Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: Case vignettes. CNS Spectr, 19, 432–438.Google Scholar

Van Putten, T. and Marder, S. R. (1986). Variable dose studies provide misleading therapeutic windows. J Clin Psychopharmacol, 6, 55–56.Google Scholar

de Oliveira, I. R., de Sena, E. P., Pereira, E. L., et al. (1996). Haloperidol blood levels and clinical outcome: A meta-analysis of studies relevant to testing the therapeutic window hypothesis. J Clin Pharm Ther, 21, 229–236.Google Scholar

Ulrich, S., Wurthmann, C., Brosz, M., et al. (1998). The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet, 34, 227–263.Google Scholar

Dahl, S. G. (1988). Pharmacokinetics of neuroleptic drugs and the utility of plasma level monitoring. Psychopharmacol Ser, 5, 34–46.Google Scholar

Farde, L., Wiesel, F. A., Halldin, C., et al. (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry, 45, 71–76.Google Scholar

Smith, M., Wolf, A. P., Brodie, J. D., et al. (1988). Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry, 23, 653–663.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar

Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R., and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279–302.Google Scholar

Kudo, S. and Ishizaki, T. (1999). Pharmacokinetics of haloperidol: An update. Clin Pharmacokinet, 37, 435–456.Google Scholar

Suzuki, A., Otani, K., Mihara, K., et al. (1997). Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics, 7, 415–418.Google Scholar

Panagiotidis, G., Arthur, H. W., Lindh, J. D., et al. (2007). Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: Impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit, 29, 417–422.Google Scholar

Fast, D. K., Jones, B. D., Kusalic, M., et al. (1986). Effect of carbamazepine on neuroleptic plasma levels and efficacy. Am J Psychiatry, 143, 117–118.Google Scholar

Spina, E. and Perucca, E. (2002). Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia, 43 Suppl2, 37–44.Google Scholar

Mylan Institutional LLC (2019). Haloperidol package insert. Rockford, IL.Google Scholar

Jann, M. W., Fidone, G. S., Hernandez, J. M., et al. (1989). Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res, 28, 153–159.Google Scholar

Raitasuo, V., Lehtovaara, R., and Huttunen, M. O. (1994). Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics: A case report. Psychopharmacology (Berl), 116, 115–116.Google Scholar

Kapur, S. and Seeman, P. (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry, 158, 360–369.Google Scholar

Giegling, I., Drago, A., Schafer, M., et al. (2010). Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res, 44, 487–492.Google Scholar

Meyer, J. M. (2017). Converting oral to long acting injectable antipsychotics: A guide for the perplexed. CNS Spectr, 22, 14–28.Google Scholar

Chang, W. H., Lin, S. K., Juang, D. J., et al. (1993). Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. Schizophr Res, 9, 35–40.Google Scholar

Harasko-van der Meer, C., Brucke, T., Wenger, S., et al. (1993). Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm, 94, 217–221.Google Scholar

Kurose, S., Mimura, Y., Uchida, H., et al. (2020). Dissociation in pharmacokinetic attenuation between central dopamine D₂ receptor occupancy and peripheral blood concentration of antipsychotics: A systematic review. J Clin Psychiatry, 81, 19r13113.Google Scholar

Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.Google Scholar

Deberdt, R., Elens, P., Berghmans, W., et al. (1980). Intramuscular haloperidol decanoate for neuroleptic maintenance therapy: Efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand, 62, 356–363.Google Scholar

Ereshefsky, L., Toney, G., Saklad, S. R., et al. (1993). A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry, 44, 1155–1161.Google Scholar

Jann, M. W., Wei, F. C., Lin, H. N., et al. (1996). Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate. Prog Neuropsychopharmacol Biol Psychiatry, 20, 73–86.Google Scholar

Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: A therapeutic window relationship. Am J Psychiatry, 149, 500–505.Google Scholar

Pilla Reddy, V., Kozielska, M., Johnson, M., et al. (2013). Population pharmacokinetic–pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale. J Clin Psychopharmacol, 33, 731–739.Google Scholar

Van Putten, T., Marder, S. R., May, P. R., et al. (1985). Plasma levels of haloperidol and clinical response. Psychopharmacol Bull, 21, 69–72.Google Scholar

Marder, S. R., Davis, J. M., and Janicak, P. G., eds. (1993). Clinical Use of Neuroleptic Plasma Levels. Washington, DC: American Psychiatric Press Inc.Google Scholar

Kapur, S., Zipursky, R., Jones, C., et al. (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry, 157, 514–520.Google Scholar

Merlo, M. C., Hofer, H., Gekle, W., et al. (2002). Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: Treatment efficacy and effects on fine motor functioning. J Clin Psychiatry, 63, 885–891.Google Scholar

Fitzgerald, P. B., Kapur, S., Remington, G., et al. (2000). Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology, 149, 1–5.Google Scholar

Lim, H. S., Kim, S. J., Noh, Y. H., et al. (2013). Exploration of optimal dosing regimens of haloperidol, a D2 antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. Pharm Res, 30, 683–693.Google Scholar

de Haan, L., van Bruggen, M., Lavalaye, J., et al. (2003). Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: A randomized, double-blind study. Am J Psychiatry, 160, 303–309.Google Scholar

Veselinovicć, T., Scharpenberg, M., Heinze, M., et al. (2019). Dopamine D2 receptor occupancy estimated from plasma concentrations of four different antipsychotics and the subjective experience of physical and mental well-being in schizophrenia: Results from the randomized NeSSy Trial. J Clin Psychopharmacol, 39, 550–560.Google Scholar

Simpson, G. M. and Kunz-Bartholini, E. (1968). Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv System, 29, 269–274.Google Scholar

Nyberg, S., Dencker, S. J., Malm, U., et al. (1998). D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol, 1, 95–101.Google Scholar

Meyer, J. M. (2020). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25, 136–144.Google Scholar

Samara, M. T., Leucht, C., Leeflang, M. M., et al. (2015). Early improvement as a predictor of later response to antipsychotics in schizophrenia: A diagnostic test review. Am J Psychiatry, 172, 617–629.Google Scholar

Leucht, S., Kane, J. M., Etschel, E., et al. (2006). Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology, 31, 2318–2325.Google Scholar

Marder, S. R. and Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. Am J Psychiatry, 151, 825–835.Google Scholar